Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities: 2021-2025

Historic Cash from Financing Activities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to $191.6 million.

  • Amylyx Pharmaceuticals' Cash from Financing Activities rose 239407.50% to $191.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.3 million, marking a year-over-year increase of 54888.68%. This contributed to the annual value of $348,000 for FY2024, which is 90.18% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $191.6 million for Q3 2025, which was up 618,183.87% from -$31,000 recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Cash from Financing Activities high stood at $232.2 million for Q4 2022, and its period low was -$1.1 million during Q4 2021.
  • Moreover, its 3-year median value for Cash from Financing Activities was $230,000 (2023), whereas its average is $23.7 million.
  • Examining YoY changes over the last 5 years, Amylyx Pharmaceuticals' Cash from Financing Activities showed a top increase of 239,407.50% in 2025 and a maximum decrease of 214.81% in 2025.
  • Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' Cash from Financing Activities stood at -$1.1 million in 2021, then soared by 21,899.25% to $232.2 million in 2022, then plummeted by 99.90% to $230,000 in 2023, then tumbled by 52.17% to $110,000 in 2024, then skyrocketed by 239,407.50% to $191.6 million in 2025.
  • Its last three reported values are $191.6 million in Q3 2025, -$31,000 for Q2 2025, and $65.7 million during Q1 2025.